Under what ticker did Seaport Therapeutics begin trading on Nasdaq?

Seaport Therapeutics began trading on the Nasdaq Global Select Market under the ticker SPTX.

Seaport Therapeutics

Timeline

PureTech's Seaport advances GlyphAgo into Phase 2 after positive Phase 1 multiple‑dose data

08:00, 9 Jun 2026

Seaport Therapeutics prices $254.9m Nasdaq IPO, London-listed PureTech gets a lift

08:37, 1 May 2026

More in Healthcare

A laboratory technician is performing an analysis in a lab setting, wearing protective gear and using pipettes. The workspace features various laboratory equipment and samples, emphasizing a research environment.

Pharma

Hansoh Phase III win bolsters GSK's global case for Ris-Rez in lung cancer

Positive overall survival data from a China trial of risvutatug rezetecan marks the first Phase III success for any B7-H3-targeted antibody-drug conjugate, strengthening GSK's broader development programme.

Updated 14:01, 10 Jul 2026

Medtech & Diagnostics

Genedrive shares lifted after Parliament boost

Updated 13:53, 10 Jul 2026

Biotech

Health & Bio Today: AstraZeneca ATTR-CM trial fails primary endpoint, Avacta, Spire Healthcare, Smith+Nephew

17:02, 9 Jul 2026

Healthcare Services

Toscafund gets four more weeks to move on Spire Healthcare bid

07:57, 9 Jul 2026

Biotech

Avacta settles £3.67m convertible bond payment in cash

07:53, 9 Jul 2026

Pharma

AstraZeneca and Ionis ATTR-CM trial fails primary endpoint

07:36, 9 Jul 2026

Medtech & Diagnostics

Smith and Nephew backs first German clinical consensus on single-use wound therapy

07:25, 9 Jul 2026

Pharma

OKYO Pharma accelerates urcosimod into Phase 3 after FDA validates trial design

13:39, 8 Jul 2026

Oil & Gas

Small Caps Today: Quadrise, Union Jack Oil, Galantas Gold, Itaconix, EDX Medical . . .

11:04, 8 Jul 2026

Biotech

Physiomics wins contracts across two service lines

10:21, 8 Jul 2026

Real Estate & REITs

Segro doubles new rent secured in first half as development pipeline hits record

09:55, 8 Jul 2026

Seaport Therapeutics is a clinical-stage biotechnology company developing oral therapies for neuropsychiatric disorders including depression and anxiety using its proprietary Glyph platform technology. The company went public on NASDAQ in April 2026 under ticker SPTX and is focused on enhancing bioavailability and reducing side effects of established therapeutic mechanisms through its platform approach.

Market: NASDAQ

Insight

What did Seaport Therapeutics report from the seven-day repeat dosing in the GlyphAgo Phase 1 programme?

Seaport Therapeutics reported that seven-day repeat dosing of GlyphAgo achieved therapeutic agomelatine exposures, reduced liver exposure, and produced no liver-related adverse events in the Phase 1 programme.

Updated 10 Jun 2026

Insight

Who founded Seaport Therapeutics and does that founder retain a stake after the IPO?

Seaport Therapeutics was founded by PureTech and founding parent PureTech Health retains a meaningful post‑IPO stake.

Updated 10 Jun 2026

Insight

How much primary capital did Seaport Therapeutics raise in its Nasdaq IPO?

Seaport Therapeutics' Nasdaq IPO provided approximately $254.9 million of primary capital.

Updated 10 Jun 2026

Insight

How much did GlyphAgo increase agomelatine bioavailability in Seaport Therapeutics' crossover data?

Crossover data showed a 6.8-fold increase in agomelatine bioavailability for GlyphAgo versus unmodified agomelatine.

Updated 10 Jun 2026

Insight

When does Seaport Therapeutics expect to start its planned Phase 2a for GlyphAgo?

Seaport Therapeutics expects Phase 2a for GlyphAgo in the second half of 2026.

Updated 10 Jun 2026

Identifiers

Ticker: SPTX
Market: NASDAQ

Learn more on:

nasdaq.com

Timeline

PureTech's Seaport advances GlyphAgo into Phase 2 after positive Phase 1 multiple‑dose data

Seaport Therapeutics prices $254.9m Nasdaq IPO, London-listed PureTech gets a lift

More in Healthcare

Hansoh Phase III win bolsters GSK's global case for Ris-Rez in lung cancer

Genedrive shares lifted after Parliament boost

Health & Bio Today: AstraZeneca ATTR-CM trial fails primary endpoint, Avacta, Spire Healthcare, Smith+Nephew

Toscafund gets four more weeks to move on Spire Healthcare bid

Avacta settles £3.67m convertible bond payment in cash

AstraZeneca and Ionis ATTR-CM trial fails primary endpoint

Smith and Nephew backs first German clinical consensus on single-use wound therapy

OKYO Pharma accelerates urcosimod into Phase 3 after FDA validates trial design

Small Caps Today: Quadrise, Union Jack Oil, Galantas Gold, Itaconix, EDX Medical . . .

Physiomics wins contracts across two service lines

Segro doubles new rent secured in first half as development pipeline hits record

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer